Australia and the ACCESS Consortium: Navigating Regulatory Collaboration
The Access Consortium is a coalition of like-minded regulatory authorities working together to promote greater regulatory collaboration and alignment of regulatory requirements. Learn how the ACCESS Consortium can streamline medicine approvals in Australia and partner countries, accelerating access to new therapies. Australia as an Early Entry Market for Medicines Australia is an increasingly attractive early…
Life Sciences Expansion Strategies Greater Bay Area – China
China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…
Australia’s TGA Priority Review Pathway
How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…
External Factors Impacting Medical Device Post-Approval Compliance
The Impact of the 3G Network Shutdown on Medical Device Post-Approval Compliance in Australia. After over two decades of service, 3G networks in Australia were officially decommissioned on October 28, 2024, to make way for faster and more reliable 4G and 5G technologies. In addition to the impact on 3G-only phones, remote areas, and smartwatches,…
2024 A Year in Review
As we approach the close of 2024, it’s essential to reflect on our achievements, growth, and the incredible progress we’ve made together. This year has been transformative, marked by milestones that position the Adjutor Healthcare Group for even greater success in 2025. As we look forward, we remain committed to innovation, collaboration, and delivering exceptional…
Advertising and Promotional Material Review for Therapeutic Goods in Australia
Navigating advertising compliance for therapeutic goods in Australia can feel like walking a tightrope. With multiple advertising laws enforced by different regulators, businesses must tread carefully to avoid penalties or legal complications.
Understanding TGA GMP Clearance
Understanding TGA Good Manufacturing Practice (GMP) requirements for Australian Regulatory Submissions Good Manufacturing Practice (GMP) is vital in ensuring the quality, safety, and efficacy of the therapeutic goods for human use (including sunscreens). In Australia, the Therapeutic Goods Administration (TGA) oversees the implementation and enforcement of GMP standards to uphold the integrity of the pharmaceutical…
Choosing the Right Regulatory Affairs Consultant
Whether you are part of an established team, a start-up, an SME, or a founder, navigating the stringent requirements of the Medical Technology, Biotechnology, and Pharmaceutical (MTP) sectors can be complex and challenging. This is where partnering with the right Regulatory Affairs Consultant becomes invaluable. Understanding the Role of a Regulatory Affairs Consultant A regulatory…
Cell and Gene Therapies Regulation
Navigating the Regulation of Cell and Gene Therapies in Australia and New Zealand Globally, cell and gene therapies are revolutionising modern medicine, offering groundbreaking treatments for life-threatening conditions including cancer, genetic disorders and rare diseases. However, despite the pace of scientific innovation, regulatory frameworks in many countries, including Australia and New Zealand, have struggled to…
Blog Posts
Follow along as we discuss the latest changes across the pharmaceutical, biotechnology, medical technology and life science sectors.